A novel oxidized low-density lipoprotein marker, serum amyloid A-LDL, is associated with obesity and the metabolic syndrome

Atherosclerosis. 2009 Jun;204(2):526-31. doi: 10.1016/j.atherosclerosis.2008.09.017. Epub 2008 Sep 27.

Abstract

Background: The putative association between the novel oxidized low-density lipoprotein markers, serum amyloid A-LDL (SAA-LDL) and alpha1-antitrypsin-LDL (AT-LDL), and obesity and the metabolic syndrome (MetS) has not been previously studied. In the present report, we investigated the levels of SAA-LDL and AT-LDL in relation to the components of the MetS. We also assessed the effect of weight reduction therapy on serum SAA-LDL and AT-LDL levels among obese subjects.

Methods: The study population included 421 obese Japanese outpatients (185 men and 236 women, mean age: 51.1 years) enrolled in the multicenter Japan Obesity and Metabolic Syndrome Study (JOMS). The novel oxidized low-density lipoprotein markers, serum SAA-LDL and AT-LDL, were measured in all participants.

Results: Circulating SAA-LDL levels were independently associated with the presence and the number of components of the MetS. SAA-LDL levels were also significantly and independently correlated with high-sensitivity C-reactive protein. Notably, successful weight reduction resulted in a significant decrease in circulating SAA-LDL concentrations. Levels of AT-LDL were not associated with the MetS.

Conclusions: We documented, for the first time, that serum SAA-LDL levels correlate positively with the number of components of the MetS and weight reduction. Whether SAA-LDL may be involved in the pathophysiology of MetS and atherosclerosis deserves further investigation.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Asian Continental Ancestry Group
  • Biomarkers / blood
  • C-Reactive Protein / metabolism
  • Diet, Reducing
  • Energy Intake
  • Exercise
  • Female
  • Humans
  • Japan / epidemiology
  • Lipoproteins, LDL / blood*
  • Male
  • Metabolic Syndrome / blood*
  • Metabolic Syndrome / ethnology
  • Middle Aged
  • Obesity / blood*
  • Obesity / ethnology
  • Obesity / therapy
  • Outpatients
  • Risk Reduction Behavior
  • Serum Amyloid A Protein / analysis*
  • Treatment Outcome
  • Weight Loss
  • alpha 1-Antitrypsin / blood

Substances

  • Biomarkers
  • Lipoproteins, LDL
  • SERPINA1 protein, human
  • Serum Amyloid A Protein
  • alpha 1-Antitrypsin
  • oxidized low density lipoprotein
  • C-Reactive Protein